Fangjin Chen
Overview
Explore the profile of Fangjin Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiao Y, Jin W, Ju L, Fu J, Wang G, Yu M, et al.
Nat Biotechnol
. 2024 May;
PMID: 38724668
Single-cell chromatin accessibility sequencing (scATAC-seq) reconstructs developmental trajectory by phenotypic similarity. However, inferring the exact developmental trajectory is challenging. Previous studies showed age-associated DNA methylation (DNAm) changes in specific genomic...
2.
Xiao Y, Jin W, Qian K, Ju L, Wang G, Wu K, et al.
Adv Sci (Weinh)
. 2024 Apr;
11(24):e2308438.
PMID: 38582099
Intratumor heterogeneity (ITH) of bladder cancer (BLCA) contributes to therapy resistance and immune evasion affecting clinical prognosis. The molecular and cellular mechanisms contributing to BLCA ITH generation remain elusive. It...
3.
Hu R, Hameed U, Sun X, Moorthy B, Zhang W, Jeffrey P, et al.
Cell Prolif
. 2022 Nov;
56(1):e13350.
PMID: 36321378
Objectives: Elimination of brain tumour initiating cells (BTICs) is important for the good prognosis of malignant brain tumour treatment. To develop a novel strategy targeting BTICs, we studied NR2E1(TLX) involved...
4.
Ren X, Wen W, Fan X, Hou W, Su B, Cai P, et al.
Cell
. 2021 Nov;
184(23):5838.
PMID: 34767776
No abstract available.
5.
Ren X, Wen W, Fan X, Hou W, Su B, Cai P, et al.
Cell
. 2021 Mar;
184(7):1895-1913.e19.
PMID: 33657410
A dysfunctional immune response in coronavirus disease 2019 (COVID-19) patients is a recurrent theme impacting symptoms and mortality, yet a detailed understanding of pertinent immune cells is not complete. We...
6.
Qian K, Wang G, Ju L, Liu J, Luo Y, Wang Y, et al.
Oncogene
. 2020 Sep;
39(44):6871-6878.
PMID: 32978518
5-10% of total prostate cancer (PCa) cases are hereditary. Particularly, immune checkpoint inhibitor-sensitive tandem duplicator phenotype (TDP) accounts for 6.9% of PCa cases, whereas genetic susceptibility genes remain completely unknown....
7.
Xu Y, Wang S, Hu Q, Gao S, Ma X, Zhang W, et al.
Nucleic Acids Res
. 2018 May;
46(W1):W374-W379.
PMID: 29750256
CavityPlus is a web server that offers protein cavity detection and various functional analyses. Using protein three-dimensional structural information as the input, CavityPlus applies CAVITY to detect potential binding sites...
8.
Chen F, Zhuo X, Qin T, Guo X, Zhang C, Lai L
Chem Biol Drug Des
. 2016 Nov;
89(5):732-740.
PMID: 27882722
Polo-like kinase 1 (Plk1), a member of polo-like kinase family, regulates multiple essential steps of the cell cycle progression. Plk1 is overexpressed in multiple cancer cell lines and considered to...
9.
Qin T, Chen F, Zhuo X, Guo X, Yun T, Liu Y, et al.
J Med Chem
. 2016 Jul;
59(15):7089-96.
PMID: 27425654
Polo-like kinase 1(Plk1) is vital for cell mitosis and has been identified as anticancer target. Its polo-box domain (PBD) mediates substrate binding, blocking of which may offer selective Plk1 inhibition...
10.
Xu Y, Dai Z, Chen F, Gao S, Pei J, Lai L
J Chem Inf Model
. 2015 Oct;
55(10):2085-93.
PMID: 26437739
Drug-induced liver injury (DILI) has been the single most frequent cause of safety-related drug marketing withdrawals for the past 50 years. Recently, deep learning (DL) has been successfully applied in...